This inventor holds 2 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: Massachusetts Eye and Ear Infirmary, The United States of America, as Represented by the Secretary, Department of Health and Human Services, Ucl Business Plc. Active years: 2019-2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 276 
2 out of 3,696 
2 out of 300 
Years Active: 2019-2021
Title: Michael A Sandberg: Innovator in Gene Therapy
Introduction
Michael A Sandberg is a notable inventor based in Reading, MA (US). He has made significant contributions to the field of gene therapy, particularly in the treatment of retinal diseases. With a total of 2 patents, Sandberg's work focuses on innovative methods to address critical ophthalmological conditions.
Latest Patents
Sandberg's latest patents include groundbreaking methods for treating human subjects with X-linked Retinitis Pigmentosa (XLRP). His approach involves administering a nucleic acid that comprises an adeno-associated viral vector containing an abbreviated human RPGR cDNA. This method aims to provide effective treatment for individuals suffering from this genetic condition, which leads to vision loss.
Career Highlights
Throughout his career, Michael A Sandberg has worked with esteemed organizations such as the Massachusetts Eye and Ear Infirmary and UCL Business Plc. His experience in these institutions has allowed him to collaborate with leading experts in the field of ophthalmology and gene therapy.
Collaborations
Some of Sandberg's notable coworkers include Basil Pawlyk and Alan Finlay Wright. Their collaborative efforts have contributed to advancing research and development in gene therapy.
Conclusion
Michael A Sandberg's innovative work in gene therapy exemplifies the potential for scientific advancements to improve the lives of individuals with genetic disorders. His contributions continue to pave the way for future research and treatment options in ophthalmology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile